ALACHUA, Fla.--(BUSINESS WIRE)--RTI Surgical Inc.™ (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced that The Journal of Spinal Disorders & Techniques published a study online highlighting nanOss® clinical data results. NanOss is an advanced bone graft substitute that is composed of nano-structured hydroxyapatite granules and an open structured engineered collagen carrier.
The Journal of Spinal Disorders & Techniques highlights peer-reviewed original articles on diagnosis, management and surgery for spinal issues. The study, published by the Journal online, is titled Use of Nanocrystalline Hydroxyapatite with Autologous BMA and Local Bone in the Lumbar Spine: A Retrospective CT Analysis of Posterolateral Fusion Results. Stephen E. Robbins, MD, orthopedic surgeon at Milwaukee Spinal Specialists, was the lead author on the study.
The study was comprised of a retrospective, multi-center, medical record review and independent analysis of CT scans that were performed in 46 patients. The 12-month postoperative CT scans determined radiographic arthrodesis rates after one-, two- or three-segment instrumented posterolateral fusions using autograft, BMA and a nanocrystalline hydroxyapatite bone void filler. The results showed that 94 percent of vertebral segments treated exhibited bilateral or unilateral posterolateral bridging bone.
NanOss’s multidimensional porosity is similar to human cancellous bone and provides a scaffold for the in-growth of new bone. It incorporates into the patient’s own newly-formed bone resulting in a fusion mass – the ultimate goal of any bone graft.
“The use of iliac crest autograft carries significant risk and creates a painful, secondary surgery site,” said Brian K. Hutchison, president and chief executive officer of RTI Surgical. “NanOss gives surgeons another bone growth option that has demonstrated equivalent fusion rates in the lumbar spine and provides an alternative for their patients. This study supports what we have heard from surgeons since the introduction of this product.”
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit http://www.rtix.com/.
Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). In addition, these statements are subject to risks associated with the Pioneer’s financial condition, business and operations and the integration of Pioneer’s business with ours. Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.
